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Abstract Apoptosis of neuronal cells apparently plays a role in
Alzheimer’s disease (AD). The amyloid beta (AL) peptide derived
from L-amyloid precursor protein is found in AD brain in vivo
and can induce apoptosis in vitro. While p53 accumulates in cells
of AD brain, it is not known if p53 plays an active role in AL-
induced apoptosis. We show here that inactivation of p53 in two
experimental cell lines, either by expression of the papillomavirus
E6 protein or by a shift to restrictive temperature, does not affect
apoptosis induction by AL (25^35), indicating that AL induces
apoptosis in a p53-independent manner.
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1. Introduction
Programmed cell death or apoptotic cell death is regularly
detected in the brain of human Alzheimer’s disease (AD) pa-
tients [1,2] and it has been suggested that apoptosis plays an
important role in the degeneration of neuronal tissue observed
in AD [3,4]. While di¡erential expression of various apopto-
sis-regulating genes was recently demonstrated in brains of
AD patients versus control groups [5], ¢nal proof for this
hypothesis is still missing. A degradation product of the L-
amyloid precursor protein (LAPP), referred to as L-amyloid
protein or AL, is found in the neuronal plaques typical for
AD (for review, see [6]). It was shown that addition of puri-
¢ed AL peptide and of its active fragment AL (25^35) can
induce apoptosis in a variety of mammalian cell types in vitro
[7^11]. These ¢ndings raise the possibility that AL may be
responsible for apoptotic cell death observed in the brains
of AD patients. This is supported by some transgenic mouse
models for AD, which display neuronal loss associated with
AL deposition (for example, see [12,13]).
From many studies in non-neuronal cell types, in particular
¢broblasts and epithelial cells, a key role for p53 as regulator
of apoptotic cell death has been inferred (for review, see [14]).
In particular, activation of p53 in response to various stress
stimuli leads to increased expression of several proapoptotic
genes, such as Bax, IGFBP-3 and Fas (for review, see [15]).
Circumstantial evidence suggests that p53 may also play a role
in apoptotic death occurring in the brain of AD patients.
Thus, it was shown that p53 expression is increased in the
brain of AD patients [16] and in the brain of AL transgenic
mice [12]. However, a functional role for p53 in AL-induced
apoptosis is not established by these studies. To address this
question, we used two experimental cell systems, derived from
normal human epithelial cells and from human osteosarcoma
cells, respectively, which have been established previously to
perform a functional analysis of p53 in a de¢ned genetic back-
ground. Since it was shown before that AL (25^35) can induce
apoptosis in various non-neuronal cell types [7,9^11,17], the
analysis of the e¡ects of AL (25^35) in our cellular system
should allow a study of the role of p53 in AL-induced apop-
tosis. The results of our experiments demonstrate that AL
(25^35) induces apoptosis in human keratinocytes as well as
the Saos-2 osteosarcoma cell line and suggest that p53 is not
essential for AL-induced apoptosis.
2. Materials and methods
2.1. Cell culture
Primary human keratinocytes were isolated from human newborn
foreskin and infected with the pLXSN retroviral vector expressing the
HPV-16 E6 and E7 genes, respectively, as described [18]. Individual
clones were selected from these cultures and expression of the viral
genes con¢rmed at the mRNA and protein level (Whitaker et al.,
manuscript in preparation). Keratinocytes were cultured in keratin-
ocyte growth medium (Promocell, Heidelberg, Germany). Saos-2 and
X4.4 cells (gifts from C. Larsen, Poitiers, France) were cultured in
DMEM (Sigma, Vienna, Austria) with 10% fetal calf serum.
2.2. AL (25^35)
For this study we used the active aggregated fragment of AL, AL
(25^35) (Sigma, Vienna, Austria). This peptide induces apoptosis in a
variety of cell types [19]. It was dissolved in water (stock solution:
1 mg/ml).
2.3. Assessment of apoptosis
Cells growing in 75 cm2 culture £asks were harvested by a 5^10 min
exposure to trypsin^EDTA (Life Technologies, Paisley, UK) and
washed twice. Cells (1^5U105) were then seeded into the wells of
six-well plates (Costar Corning, NY, USA) and cultured for 24 h in
growth medium. Thereafter, the cells were washed and AL (25^35)
was added to the culture medium at concentrations of 2, 5 and 10
Wg/ml. The cells were incubated for 24 h. For the assessment of
apoptosis, cells were harvested by application of trypsin^EDTA
(Life Technologies, Paisley, UK), washed twice in phosphate bu¡ered
saline (PBS) and then gently resuspended in 200 Wl propidium iodide
(PI; Sigma, Vienna, Austria) with Triton X-100 (0.1%; Sigma, Vien-
na, Austria). The PI £uorescence of individual nuclei was measured
using a FACS scan £ow cytometer (program CellQuest, Becton Dick-
inson, Mountain View, USA). Red £uorescence due to PI staining of
DNA was expressed on a logarithmic scale and the forward scatter
(FSC) of particles was measured simultaneously. Five thousand events
were measured on the scatter gate. All measurements were performed
under identical instrumental settings. This technique identi¢es a pop-
ulation of apoptotic nuclei that has a lower £uorescence intensity than
diploid nuclei but is clearly distinct from debris and non-viable cells.
The number of apoptotic nuclei is expressed as a percentage of the
total number of events. Nuclear labelling with propidium iodide is a
quick and reliable method for the assessment of apoptosis which is
used by many laboratories [20^22]. Apoptosis detection by Annexin V
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 1 3 2 3 - 5
*Corresponding author. Fax: (43)-512-583919 8.
E-mail: p.jansen-duerr@oeaw.ac.at
FEBS 23462 16-3-00
FEBS 23462 FEBS Letters 470 (2000) 221^225
binding was carried out by using Annexin V (human recombinant,
Alexis Biochemicals, La«ufel¢ngen, Switzerland) according to the man-
ufacturer’s recommendations.
2.4. Western blotting
Equal amounts of protein (20 Wg pro lane) were separated on a
12.5% SDS^PAGE gel. After wet transfer on a PVDF membrane
(Boehringer Mannheim, Germany), ¢lters were blocked with non-fat
milk and incubated with primary monoclonal antibodies Anti-p53
(clone Do-1, Santa Cruz Biotechnologies, Heidelberg, Germany),
Anti-Bax (B-9, Santa Cruz Biotechnologies), Anti-Bcl-2 (Clone 124,
Boehringer Mannheim), p21(WAF-1) (Santa Cruz Biotechnologies)
and cdk4 (Transduction Laboratories, Hamburg, Germany). The ¢l-
ters were then incubated with a secondary, horseradish peroxidase-
conjugated, goat anti-mouse antibody (Dako, Glostrup, Denmark)
and the protein bands were visualized with a chemiluminescent sub-
strate detection system ECL (Amersham, Vienna, Austria). The quan-
ti¢cation of Western blots was performed by densitometric scanning
of the autoradiograms; expression of M2 pyruvate kinase served as an
internal standard and loading control.
3. Results and discussion
To determine the role of p53 in AL-mediated apoptosis,
human keratinocytes were used in which p53 had been inacti-
vated by stable expression of the E6 oncogene encoded by
human papillomavirus type 16 (HPV-16) from a E6-express-
ing retroviral vector ([18]; Whitaker, manuscript in prepara-
tion). It has previously been shown that E6 triggers degrada-
tion of p53 via the ubiquitin^proteasome pathway [23], an
activity which depends on a third protein, E6-AP which serves
as speci¢c ubiquitin ligase for p53 (for recent review, see [24]).
E6-expressing keratinocytes in early culture can grow inde¢-
nitely but, unlike many p53-de¢cient tumor cells, do not dis-
play a grossly transformed phenotype. To determine the role
of p53 for AL-induced apoptosis under physiological condi-
tions, the e¡ects of AL on E6-expressing keratinocytes were
compared with results obtained in primary keratinocytes. As a
further control, human keratinocytes expressing the E7 gene
of HPV-16 were used. It has previously been shown that E7
binds and inactivates the proteins encoded by the retinoblas-
toma gene family (for review, see [25]). E7 does not reduce the
stability of p53, but rather leads to its accumulation and p53
may well play a role for the well-documented induction of
apoptosis by HPV-16 E7 [26]. When the p53 status of the
three cell types was compared by Western blotting, we found
that, as expected, p53 was easily detected in primary kerati-
nocytes but absent from E6-expressing cells (Fig. 1) and ex-
pression of p21 followed the expression pattern of p53. The
levels of both p53 and p21 were signi¢cantly induced in E7-
expressing cells, in keeping with the reported ability of E7 to
induce stabilization of p53 [26].
To directly determine the ability of AL to induce apoptosis
in our keratinocyte model, the cells were incubated with in-
creasing concentrations of an amyloidogenic peptide. While
AL (1^42) is the amyloidogenic peptide that is usually ob-
served in AD brains, its experimental use is hampered by its
limited in vitro stability in an aggregated, ¢brillary state. A
shorter peptide, referred to as AL (25^35), is currently used in
most of the published literature since it is aggregated and
reasonably stable in vitro. Furthermore, it was shown that
AL (25^35) and AL (1^42) display very similar biological ac-
tivity in vitro (for example, see [10,17,27,28]). When AL (25^
35) was added to primary keratinocytes, a signi¢cant and
dose-dependent increase in the percentage of apoptotic cells
was observed (Fig. 2A), resulting in a nearly ¢ve-fold increase
in apoptotic cell death at an AL (25^35) concentration of 10
Wg/ml. As shown in Fig. 2B, more than 30% of the total cell
population undergo apoptosis at 24 h after addition of AL
(25^35), indicating that AL (25^35) provides a strong apop-
totic signal for human keratinocytes, as was observed in other
cell types before [7,9^11,17]. To address the role of p53 for
AL-induced apoptosis, the experiment was repeated with the
E6-expressing keratinocyte line, which does not contain de-
tectable amounts of p53 protein (Fig. 1). Surprisingly, a
strong apoptotic e¡ect was induced by AL (25^35) also in
this cell line (Fig. 2A and B), which is similar to the e¡ect
seen in primary keratinocytes expressing normal levels of p53.
When AL (25^35) was added to E7-expressing cells, expressing
elevated levels of p53 protein, again a strong apoptotic e¡ect
was observed, further supporting the conclusion that the ex-
pression level and function of p53 is irrelevant for AL-induced
apoptosis. AL-induced apoptosis was also analyzed by the
Annexin V detection system, which is based on the exposure
of phosphatidylserine to the extracellular medium, an early
event in apoptosis (for review, see [29]). Using this method,
again a p53-independent induction of apoptosis by AL (25^35)
was observed (Fig. 2C).
The results shown above indicate that inactivation of p53
by HPV-16 E6 does not a¡ect AL-induced apoptosis, while E6
does suppress apoptosis induced by other stimuli [30^32],
most likely by inactivating p53, a key regulator of apoptosis.
While speci¢c inactivation of p53 by E6 appears to be a nor-
mal consequence of HPV infection, it is now clear that E6 also
a¡ects the function of other cellular proteins di¡erent from
p53 (for review, see [33]). We therefore also wanted to analyze
the role of p53 in AL-mediated apoptosis in a di¡erent cellular
background. While the data shown in Fig. 2 clearly indicate
that p53 is dispensable for AL-mediated apoptosis in our
keratinocyte model system, we were interested to know if
short term modulation of p53 function may a¡ect apoptosis
Fig. 1. The expression of p53 and p21 in primary keratinocytes
(HFK) and in cells immortalized with HPV-16 E6 or E7 protein is
shown in a Western blot. HPV-16 E6 immortalized keratinocytes do
not contain detectable p53 and p21 proteins.
Table 1
The in£uence of AL (25^35) (10 Wg/ml) on the induction of apopto-
sis in X4.4 and Saos-2 cells at 32 and 37‡C, respectively
32‡C 37‡C
Co AL (25^35) Co AL (25^35)
X4.4 1.7 þ 0.4 14.5 þ 1.2 1.8 þ 0.7 11.2 þ 3.7
Saos-2 1.5 þ 0.1 19.2 þ 1.5 2.4 þ 0.7 12.0 þ 0.8
Results represent the percentages of apoptotic cells (x þ S.E.M.,
n = 5) after a 24 h incubation.
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Fig. 2. A: The in£uence of the expression of p53 on the induction of apoptosis by AL (25^35) (2, 5 and 10 Wg/ml) in primary keratinocytes or
cells immortalized with HPV-16 E6 and E7 protein. The keratinocytes immortalized with HPV E6 (horizontally hatched bars) do not contain
detectable p53 protein. In contrast primary keratinocytes (open bars) and keratinocytes immortalized with E7 protein (diagonally hatched bars)
produce p53. The error bars represent x þ S.E.M. (n = 6). B: A representative experiment of a FACS £ow-cytometry analysis on the induction
of apoptosis by AL (25^35, 10 Wg/ml) in primary keratinocytes or cells immortalized with HPV-16 E6 and E7. Analysis was performed by de-
termination of forward scatter (x-axis) and propidium iodide staining (y-axis). C: FACS £ow-cytometry analysis by annexin V staining. AL
(25^35, 10 Wg/ml) was added to keratinocytes immortalized with HPV-16 E6 and HPV-16 E7, respectively. Apoptosis was analyzed by determi-
nation of propidium iodide staining (x-axis) and annexin V binding (y-axis), respectively.
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induction by AL. To this end, a cell line with inducible p53
function was used.
We used the p53 gene from Xenopus laevis (Xl-p53) which
behaves as a temperature-sensitive mutant of p53 [34]. Saos-2
cells, a p53-de¢cient human osteosarcoma cell line, had been
stably transfected with an expression vector for Xl-p53, to
yield the cell line X4.4. Saos-2 and X4.4 cells were grown at
37‡C, where Xl-p53 is inactive. Upon shifting the temperature
to 32‡C, Xl-p53 becomes fully active [34]. Cells were grown at
37‡C or shifted to 32‡C for 24 h, to activate Xl-p53 function.
Activation of p53 function was monitored by determining the
expression of p21(WAF-1), a well-established target gene for
p53-dependent trans-activation [35]. As is shown by Western
blot analysis in Fig. 3, expression of p21(WAF-1) was
strongly induced by the temperature shift in X4.4 but not
the parental Saos-2 cells, con¢rming the functional activation
of the temperature-sensitive p53 protein. Subsequently, AL
(25^35) was added and the amount of apoptosis determined.
This experiment revealed that in the absence of any functional
p53 (i.e. in cells grown at 37‡C), AL (25^35) induces a 5^6-
fold increase of apoptosis in both Saos-2 and X4.4 cells. When
shifted to 32‡C, there was no signi¢cant change in the suscep-
tibility to AL (25^35)-induced apoptosis (Table 1). These re-
sults clearly indicate that p53 function is not involved in AL-
mediated apoptosis, in agreement with the results obtained in
keratinocytes (Fig. 2).
The data reported here indicate that apoptosis induced by
AL (25^35) is not dependent on p53, suggesting that AL can
induce apoptosis via a p53-independent pathway. Our ¢ndings
would suggest that the increased levels of p53 in AD brains
[16] are not linked to apoptosis induced by AL. It is conceiv-
able that other proteins are responsible for AL-induced cell
death in AD brain tissue. Bax, a protein that promotes apop-
tosis, was also found at increased concentrations in dystrophic
neurites of senile plaques [36] and the Bax-related protein Bcl-
2 is overexpressed in reactive glial cells surrounding senile
plaques [37]. Kim et al. [38] reported that AL (25^35) de-
creases Bcl-2 mRNA expression, as well the ratio of the anti-
apoptotic and pro-apoptotic proteins Bcl-xl/Bcl-xs. To study a
potential role of Bax/Bcl-2 for apoptosis induction in our ex-
perimental system, the expression of both genes was analyzed
by Western blot. We found that expression of the Bax protein
is slightly increased upon AL (25^35)-treatment in both the
E6-expressing and E7-expressing keratinocytes; in contrast,
expression of Bcl-2 is not detectable in either cell line (Fig.
Fig. 3. X4.4 and Saos-2 were grown at 37‡C or shifted to 32‡C for
24 h, as indicated. The expression of p21(WAF-1) was determined
by Western blot. The p53 protein from Xenopus laevis is not recog-
nized by the p53 antibodies available to us, which are directed to
the human protein. As a loading control, Western blots were re-
probed with antibodies to cdk4.
Fig. 2 (continued).
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4). These results imply a moderate increase of Bax in AL (25^
35)-induced apoptosis in immortalized keratinocytes. While
our present results indicate that apoptosis may occur via
p53-independent pathways in the AD brain, more work is
required to unravel signalling pathways leading to AL-induced
apoptotic cell death.
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